Exagen Inc. (NASDAQ:XGN) Major Shareholder Nmsic Co-Investment Fund, L.P. Sells 200,000 Shares

Exagen Inc. (NASDAQ:XGN) major shareholder Nmsic Co-Investment Fund, L.P. sold 200,000 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $3.30, for a total value of $660,000.00. Following the completion of the transaction, the insider now owns 2,108,958 shares in the company, valued at $6,959,561.40. This trade represents a 8.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Exagen Stock Performance

XGN stock opened at $3.84 on Thursday. Exagen Inc. has a 1 year low of $1.30 and a 1 year high of $4.83. The company has a fifty day simple moving average of $2.96 and a 200 day simple moving average of $2.53. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 1.54.

Exagen (NASDAQ:XGN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. The company had revenue of $12.51 million during the quarter, compared to analysts’ expectations of $13.55 million. Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. During the same quarter in the previous year, the firm earned ($0.31) earnings per share. As a group, research analysts expect that Exagen Inc. will post -0.87 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, William Blair reissued an “outperform” rating on shares of Exagen in a research note on Wednesday, November 13th.

Institutional Investors Weigh In On Exagen

A number of large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its holdings in Exagen by 93.3% during the second quarter. Renaissance Technologies LLC now owns 94,234 shares of the company’s stock valued at $172,000 after acquiring an additional 45,476 shares during the period. Creative Planning bought a new position in Exagen in the 3rd quarter worth approximately $110,000. Palumbo Wealth Management LLC lifted its holdings in shares of Exagen by 14.5% during the third quarter. Palumbo Wealth Management LLC now owns 76,364 shares of the company’s stock worth $236,000 after buying an additional 9,695 shares during the last quarter. Verus Capital Partners LLC bought a new stake in shares of Exagen in the third quarter valued at approximately $39,000. Finally, Stonepine Capital Management LLC grew its stake in shares of Exagen by 49.0% in the third quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock worth $1,651,000 after acquiring an additional 175,701 shares during the last quarter. Institutional investors own 75.25% of the company’s stock.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).